Ipsen’s Kayfanda® Gets EU Approval for Rare Liver Disease
Company Announcements

Ipsen’s Kayfanda® Gets EU Approval for Rare Liver Disease

Ipsen (FR:IPN) has released an update.

Ipsen’s drug Kayfanda® (odevixibat) has received EU approval to treat cholestatic pruritus in patients over six months old with Alagille Syndrome, a rare liver disease. The approval is based on Phase III trial results which demonstrated significant improvement in itch severity and sleep quality, with a safety profile similar to placebo. This marks a significant advancement in Ipsen’s portfolio for rare cholestatic liver diseases, also noted for their recent EU approval of Iqirvo® (elafibranor) for Primary Biliary Cholangitis.

For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskIpsen Wins Second Shingo Prize for Excellence
TipRanks European Auto-Generated NewsdeskIpsen’s New PBC Treatment Iqirvo Gains EU Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App